Penetration of orally administered prulifloxacin into human lung tissue

Clinical Pharmacokinetics

Volumn 44, Issue 12, 2005, Pages 1287-1294

  Concia, Ercole ^a   Allegranzi, Benedetta ^a   Ciottoli, Giovanni B ^b   Orticelli, Giovanna ^b   Marchetti, Marcello ^b   Dionisio, Paolo ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HEMOGLOBIN; PRULIFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; FEMALE; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG PARENCHYMA; LUNG RESECTION; LUNG TUMOR; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUPERNATANT; TISSUE DISTRIBUTION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; AGED; ANTI-INFECTIVE AGENTS; DIOXOLANES; FEMALE; FLUOROQUINOLONES; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PNEUMONECTOMY; QUINOLONES;

EID: 29244489509     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544120-00007     Document Type: Article

References (24)

1. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-34
2. Tougou K, Nakamura A, Watanabe S, et al. Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998; 26 (4): 355-9
3. Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittel Forschung 2003; 53 (3): 201-5
4. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34: 930-7
5. Adams SG, Anzueto A. Antibiotic therapy in acute exacerbation of chronic bronchitis. Semin Respir Infect 2000; 15 (3): 234-47
6. Prats G, Roig C, Miro E, et al. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21 (4): 328-34
7. Montanari MP, Mingoia M, Varaldo PE. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. An-timicrob Agents Chemother 2001; 45 (12): 3616-22
8. Grassi C, Salvatori E, Rosignoli MT, et al. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002; 69 (3): 217-22
9. Ritrovato CA, Deeter RG. Respiratory tract penetration of quinolone antimicrobials: a case in study. Pharmacotherapy 1991; 11 (1): 38-49
10. Lee LJ, Sha X, Gotfried MH, et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998; 18 (1): 35-41
11. Danesi R, Lupetti A, Barbara C, et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 2003; 51 (4): 939-45
12. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46 (5): 1475-80
13. Cazzola M, Blasi F, Terzano C, et al. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am J Respir Med 2002; 1 (4): 261-72
14. Müller M, dela Peña A, Derendorf H. Issues in pharmacokinet-ics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48 (5): 1441-53
15. Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. Am J Med 1987; 82 Suppl. 4A: 202-7
16. Honeybourne D, Wise R, Andrews JM. Ciprofloxacin penetration into lungs [letter]. Lancet 1987; I: 1040
17. Herker H, Muller MR, Kreischitz N, et al. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med 2002; 165: 273-6
18. Von Baum H, Bottcher S, Hoffmann H, et al. Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. J Antimicrob Chemother 2001; 47 (5): 729-30
19. Baldwin DR, Wise R, Andrews JM, et al. Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax 1991; 46 (9): 658-62
20. Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdyalisis. Antimicrob Agents Chemother 2004; 48 (6): 2228-32
21. Joukhadar C, Muller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005; 44 (9): 895-913
22. Serour F, Dan M, Gorea A, et al. Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams. Antimicrob Agents Chemother 1991; 35 (2): 380-1
23. Wise R, Baldwin DR, Andrews JM, et al. Comparative pharmacokinetic disposition of fluoroqunolones in the lung. J Antimicrob Chemother 1991; 28 Suppl. C: 65-71S
24. Couraud L, Fourtillan JB, Saux MC, et al. Diffusion of ofloxacin into human lung tissue. Drugs 1987; 34 Suppl. 1: 37-8